U.S. Magnetic Resonance Imaging Market Overview
The U.S. magnetic resonance imaging market was valued at USD 2.52 billion in 2025 and is forecast to reach USD 3.95 billion by 2035, expanding at a compound annual growth rate of 4.6% during 2026–2035. The calculation follows the established scope of MRI systems, related coils, software upgrades and system-level service value directly attached to an MRI installation. It excludes stand-alone radiology information systems, unrelated image-management software and MRI contrast media.
MRI is an essential diagnostic modality across neurology, orthopedics, oncology, cardiology and abdominal imaging because it produces detailed soft-tissue images without ionizing radiation. The next decade will be shaped less by a simple increase in scanner counts and more by replacement of aging installed systems, expansion of outpatient imaging, faster acquisition software, lower-helium magnet designs and wider use of MRI in treatment planning and image-guided procedures.
Hospitals and imaging centers are seeking more scans from each installed unit without lowering diagnostic confidence. Vendors are responding with deep-learning reconstruction, automated positioning, protocol guidance, motion correction and workflow software. These functions can shorten acquisition or setup time and make protocol execution more consistent across technologists. At the same time, compact and low-field systems are opening sites that cannot support the weight, shielding, power and cryogenic requirements of a conventional high-field room.
The forecast starts from a modeled 2025 U.S. revenue base and applies a 4.6% annual growth rate, consistent with the growth direction published on the existing market page. The resulting values are USD 2.64 billion in 2026, USD 3.30 billion in 2031 and USD 3.95 billion in 2035. Revenue growth reflects new equipment, replacement systems, coils, qualifying upgrades and attached service contracts; it is not a count of examinations or installed scanners.
Key Highlights
- The market is valued at USD 2.52 billion in 2025 and is forecast to reach USD 3.95 billion by 2035.
- Revenue is projected to increase at a 4.6% CAGR from 2026 through 2035.
- Closed MRI systems account for an estimated 84% of 2025 revenue, equal to USD 2.12 billion.
- Systems operating at 1.5T and above generate an estimated 74% of 2025 revenue, equal to USD 1.86 billion.
- Musculoskeletal imaging leads applications with an estimated 29% share, or USD 0.73 billion, in 2025.
- Hospitals hold an estimated 59% of end-user revenue, while freestanding diagnostic imaging centers hold 31%.
- The South leads regional demand with an estimated 36% share; California is the largest state market with 13% of U.S. revenue.
- AI reconstruction, low-helium magnets and faster workflows are becoming core purchasing criteria rather than optional upgrades.
Strategic Takeaways
- Replacement demand offers the clearest route to near-term equipment revenue.
- Scan-time reduction can deliver more value than incremental magnet performance alone.
- Low-helium designs reduce siting risk and exposure to cryogen supply constraints.
- Outpatient centers favor systems with predictable service costs and high daily throughput.
- 1.5T remains the volume standard, while 3T wins advanced neuro, oncology and research tenders.
- Low-field MRI can expand access in community, emergency and space-constrained settings.
- Vendors that integrate hardware, reconstruction software and lifecycle service will defend pricing more effectively.
Market Dynamics
Growth Drivers
The installed base is entering a sustained replacement cycle. MRI scanners remain in service for many years, but older platforms can carry slower gradients, limited coil channels, higher helium requirements and software that cannot support newer reconstruction or workflow tools. A replacement decision can therefore improve image quality, raise throughput and lower facility risk in one capital project. Health systems with multiple hospitals also use replacements to standardize protocols and service arrangements across their networks.
Clinical demand continues to broaden. An aging population increases the need for brain, spine, joint, cardiac and cancer imaging. MRI is also gaining relevance in prostate assessment, breast imaging, liver characterization, radiotherapy planning and treatment response. The value of these examinations supports demand for advanced coils, diffusion sequences, cardiac packages and quantitative analysis rather than basic anatomical imaging alone.
Workflow automation is another measurable purchasing factor. Automated patient setup, protocol selection, scan planning, reconstruction and quality checks reduce repeat work and help technologists handle complex examinations. Deep-learning reconstruction can preserve usable image quality at faster acquisition settings, which raises the productive capacity of an existing scanner. This feature is important in locations where hiring another technologist or adding a second MRI room is difficult.
Outpatient migration supports equipment purchases outside large hospitals. Independent imaging groups, orthopedic networks and multispecialty practices need systems that fit tighter room footprints and offer a workable cost per scan. Wide-bore 1.5T systems, compact low-field platforms and refurbished units address different parts of that demand. The outpatient channel also increases the importance of uptime guarantees, remote support and fixed-price service.
Market Restraints
MRI remains a capital-intensive modality. A project includes the scanner, radiofrequency shielding, construction, cooling, electrical work, quench planning, coils, software, service and staff training. Site preparation can materially increase the installed cost, especially in an existing building. Smaller providers may delay a purchase when borrowing costs, reimbursement uncertainty or construction constraints weaken the return on investment.
Labor availability limits capacity. MRI technologists require specialized training, and complex examinations can be difficult to standardize across shifts and sites. Radiologist shortages can also create reporting backlogs even when scanner capacity exists. Automation addresses part of the workflow burden, but it does not remove the need for qualified staff, patient screening and clinical oversight.
Reimbursement and prior authorization can suppress examination growth. Commercial payer rules vary by indication, and an authorization delay can leave a scanner slot unused. Medicare payment changes influence both hospital outpatient departments and independent diagnostic testing facilities. Providers therefore assess system economics using payer mix, expected protocol duration, denial rates and service expense, not equipment price alone.
Patient access and safety remain operational constraints. Claustrophobia, body size, implanted devices, motion and the need for sedation can prevent or complicate an examination. Wide-bore and open designs improve access for selected patients, while faster protocols reduce the time a patient must remain still. MRI safety procedures for implants, screening and controlled access remain mandatory regardless of scanner design.
Market Opportunities
The strongest commercial opportunity is an upgrade-led replacement proposition. A vendor can combine a new magnet or scanner with AI reconstruction, coils, protocol conversion, staff training and multi-year service. This package gives a health system a defined migration path and reduces downtime during the switch. It also creates recurring software and service revenue after installation.
Low-helium and sealed-magnet platforms offer a second opportunity. Conventional magnets require substantial helium infrastructure and quench planning. Systems that retain only a small sealed helium charge can reduce construction complexity and protect the operator from helium loss. This advantage is especially relevant in urban buildings, outpatient centers and sites without a conventional vent route.
Low-field MRI can create new demand rather than only displace high-field equipment. Lower-field systems can require less shielding, power and structural reinforcement, enabling deployment near emergency, intensive-care or community settings. Their success will depend on clinically validated use cases, reimbursement, image reconstruction and proof that the system improves access or speed without creating downstream repeat imaging.
MRI-guided intervention and radiotherapy planning are smaller but higher-value opportunities. Cardiac electrophysiology, radiation oncology and focused therapy workflows can use MRI's soft-tissue contrast during planning or treatment. These applications require dedicated software, compatible devices, room design and clinical training, which creates partnerships between scanner vendors, therapy companies and specialist consumable suppliers.
Market Segmentation Analysis
By System Type
Closed MRI systems generated an estimated 84% of U.S. market revenue in 2025, equal to USD 2.12 billion. Their lead comes from strong signal performance, broad clinical validation and a large installed base of 1.5T and 3T systems. Wide-bore closed designs have reduced some of the comfort limitations associated with traditional narrow bores and now serve routine hospital and outpatient demand. Open MRI systems represented the remaining 16%, or USD 0.40 billion. They are used for claustrophobic, bariatric and positional imaging needs, but lower field strength and a narrower range of advanced protocols limit their revenue share.
Closed systems are forecast to retain more than four-fifths of revenue through 2035. Open and compact designs can still grow faster from a smaller base as reconstruction software improves image quality and outpatient sites seek less demanding installations. The competitive distinction will increasingly be based on bore diameter, table capacity, acoustic experience, scan duration and exam availability rather than the open-versus-closed label alone.
By Field Strength
High-field platforms operating at 1.5T and above accounted for an estimated 74% of 2025 revenue, or USD 1.86 billion. Within this group, 1.5T remains the workhorse for broad clinical use because it balances image quality, protocol breadth, operating expense and implant compatibility. Premium 3T systems command higher prices and are favored for neuroscience, oncology, musculoskeletal imaging, cardiac work and academic research. Ultra-high-field systems above 3T represent a limited research-led niche and do not materially change the national revenue mix.
Medium-field equipment generated an estimated 18% share, equal to USD 0.45 billion. This category benefits from compact installations and clinical performance that can support routine examinations. Low-field systems held an estimated 8%, or USD 0.20 billion. Their commercial role is expanding as advanced reconstruction improves image utility and as providers assess MRI for bedside, emergency and community settings. Even with faster low-field growth, high-field systems will retain the largest revenue pool through 2035 because advanced clinical pathways and replacement tenders favor 1.5T and 3T platforms.
By Application
Musculoskeletal MRI led the market with an estimated 29% share in 2025, representing USD 0.73 billion of system-related revenue. High volumes of knee, shoulder, spine and sports-injury examinations support this position across hospitals, orthopedic practices and imaging centers. Neurology followed with 25%, or USD 0.63 billion, supported by brain, spine, stroke, epilepsy, multiple sclerosis and neurodegenerative disease imaging.
Oncology accounted for an estimated 19% share, equal to USD 0.48 billion. Growth comes from lesion characterization, staging, therapy planning and longitudinal response assessment, including prostate, breast, liver and rectal imaging. Cardiology represented 10%, or USD 0.25 billion. Cardiac MRI remains protocol- and expertise-intensive, but tissue characterization and functional assessment support higher clinical use in specialist centers.
Gastrointestinal and abdominal applications produced an estimated 9% share, or USD 0.23 billion, while other applications—including breast, vascular, pelvic and research imaging—held 8%, or USD 0.20 billion. Oncology and cardiac applications are expected to outpace routine musculoskeletal work through 2035 because vendors are introducing faster motion-resolved imaging, automated cardiac planning and treatment-linked MRI workflows.
By End User
Hospitals accounted for an estimated 59% of 2025 revenue, equal to USD 1.49 billion. Their share reflects higher equipment intensity, 24-hour emergency coverage, inpatient referrals, complex cases and purchases of premium 3T or specialty systems. Academic medical centers also invest in advanced gradients, research software and multi-coil configurations that lift revenue per installation.
Freestanding diagnostic imaging centers held an estimated 31% share, or USD 0.78 billion. These operators emphasize utilization, scheduling efficiency, payer contracts and lifecycle cost. Wide-bore 1.5T scanners are central to this setting, while selected centers use 3T systems to differentiate advanced neuro, prostate or musculoskeletal services. Ambulatory surgery centers, specialty clinics and other sites represented 10%, equal to USD 0.25 billion. This group is set to record the fastest percentage growth as compact scanners and site-light designs reduce installation barriers.
U.S. Regional and State-Level Analysis
The South represented an estimated 36% of U.S. MRI market revenue in 2025, equal to USD 0.91 billion. Its lead reflects population size, continued migration, hospital construction and large outpatient networks in Texas, Florida, Georgia, North Carolina and Tennessee. Texas generated an estimated 9% of national revenue, or USD 0.23 billion, while Florida held 7%, or USD 0.18 billion. Replacement projects in major metropolitan areas and new outpatient capacity will keep the South in first place through 2035.
The West held an estimated 25% share, equal to USD 0.63 billion. California alone represented 13% of the national market, or USD 0.33 billion, making it the largest state opportunity. The state's academic centers, integrated delivery networks, cancer programs and dense outpatient imaging base support demand for both high-end 3T systems and workflow upgrades. Washington, Arizona and Colorado add demand from expanding urban health systems and specialty practices.
The Midwest accounted for an estimated 21% of revenue, or USD 0.53 billion. Illinois led the region with 4% of national revenue, equal to USD 0.10 billion, followed by sizeable markets in Ohio, Michigan and Minnesota. Purchasing is concentrated in regional health systems that often negotiate multi-site equipment and service agreements. The region's opportunity is weighted toward fleet standardization, replacement of aging 1.5T systems and deployment of efficient scanners in secondary cities.
The Northeast generated an estimated 18% share, equal to USD 0.45 billion. New York held 6% of U.S. revenue, or USD 0.15 billion, while Pennsylvania, Massachusetts and New Jersey formed the next tier. The Northeast has a dense concentration of teaching hospitals and advanced specialty programs, supporting premium neuro, oncology and cardiac systems. Space constraints and high construction costs also strengthen the case for low-helium magnets, compact footprints and upgrades that extend the productive life of an existing room.
These state and regional figures represent 2025 demand estimates built from population, provider concentration, imaging capacity, health-system investment and specialty-care intensity. They measure market revenue by customer location; they do not measure where scanners are manufactured.
Competitive Landscape
The U.S. market is concentrated among global imaging companies with broad hardware, software and service portfolios. Competition occurs at the level of field strength, gradient performance, bore design, coils, reconstruction speed, workflow automation, helium requirements, service uptime and installed-room conversion. A vendor's ability to convert protocols, train staff and maintain uptime across a health-system fleet can carry as much weight as the magnet specification.
Key participants include GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems USA, Fujifilm Healthcare Americas, Esaote North America, FONAR, United Imaging Healthcare and Hyperfine. Premium systems compete for academic, neurological, cardiac and oncology programs, while value-oriented and refurbished platforms address outpatient centers and community hospitals. Low-field and portable developers add a separate competitive layer focused on access, siting and point-of-care use.
Detailed Company Profiles
GE HealthCare
GE HealthCare supplies MRI systems, coils, reconstruction software, clinical applications and lifecycle services in the United States. Its SIGNA portfolio spans conventional clinical systems and advanced research platforms. Relevant offerings include SIGNA Artist and SIGNA Voyager at 1.5T, SIGNA Premier and SIGNA Architect at 3T, and the next-generation SIGNA Bolt 3T platform. The company's AIR family combines lightweight coil technology with AIR Recon DL deep-learning reconstruction, while Sonic DL targets faster acquisitions for selected applications.
GE HealthCare's MRI position is built around a large U.S. installed base, direct service coverage and the ability to bundle scanners with imaging software and pharmaceutical diagnostics. Its 2026 MR announcements added the SIGNA One workflow environment, the SIGNA Sprint with Freelium sealed configuration and expanded research tools. These products address throughput, protocol consistency and helium dependence. The commercial opportunity lies in converting legacy SIGNA rooms to current platforms while retaining customer workflows and service relationships.
Siemens Healthineers
Siemens Healthineers markets the MAGNETOM MRI family in the United States. Its portfolio includes MAGNETOM Free.Max and Free.Star low-field systems, MAGNETOM Altea and Sola 1.5T platforms, MAGNETOM Vida and Lumina 3T platforms, and MAGNETOM Terra.X for ultra-high-field research and clinical use where cleared. The company pairs these systems with BioMatrix sensor technology, Deep Resolve reconstruction and myExam workflow automation.
The Free platform is strategically important because its compact magnet and lower infrastructure requirements address sites that may not accommodate a conventional MRI suite. At the premium end, high-gradient and 3T systems target advanced neuro, cardiac and oncology work. Siemens Healthineers also supports enterprise purchasing through service, digital tools and long-term value partnerships. FDA clearance recorded on September 1, 2026 for updated MAGNETOM Free.Max and Free.Star configurations reinforces the company's U.S. low-field position.
Philips
Philips offers 1.5T and 3T MRI systems, imaging software, coils, service and radiotherapy-planning solutions. Its U.S. portfolio includes Ingenia Ambition and MR 5300 1.5T systems and Ingenia Elition 3T. BlueSeal magnet technology uses a sealed helium circuit with seven liters of helium, reducing dependence on conventional helium infrastructure. SmartSpeed combines Compressed SENSE and AI-based reconstruction to support faster imaging and higher image quality.
Philips is extending MRI beyond routine diagnosis. The company's 4D MR-RT solution supports motion-resolved, multi-contrast radiotherapy simulation, while its collaboration with Imricor connects a 1.5T platform with MR-compatible cardiac electrophysiology tools. These initiatives link scanner revenue to oncology and interventional workflows. Philips can use its installed base, informatics and image-guided therapy presence to sell integrated solutions rather than stand-alone systems.
Canon Medical Systems USA
Canon Medical Systems USA supplies the Vantage MRI portfolio, including Vantage Orian 1.5T, Vantage Fortian 1.5T and Vantage Galan 3T systems. The company emphasizes patient access, quiet operation, workflow and image reconstruction. AiCE uses deep-learning reconstruction to reduce noise and support image quality, while Advanced intelligent Clear-IQ Engine and automation features are integrated across selected configurations. Canon also offers coils, clinical applications and service for neuro, body, musculoskeletal, cardiac and oncology imaging.
Canon's opportunity is strongest where providers want a broad clinical system with a patient-friendly bore, quiet sequences and predictable room operation. Vantage Fortian is positioned around workflow assistance and remote support, while Vantage Galan serves higher-end 3T needs. Its U.S. direct sales and service organization supports hospital and outpatient accounts, and its wider diagnostic-imaging portfolio enables multi-modality procurement.
Recent Developments: March 15–September 15, 2026
- On September 1, 2026, the U.S. FDA issued a substantially-equivalent decision for Siemens' MAGNETOM Free.Max and MAGNETOM Free.Star under 510(k) K260758. The decision supports continued commercialization of the updated low-field MRI configurations in the United States and confirms regulatory activity in compact MRI.
- On August 27, 2026, Philips and Imricor announced an interventional MRI laboratory solution combining a Philips 1.5T system, cardiac MR workflow and Imricor's MR-compatible mapping, recording and catheter technologies. Some configurations are commercially available in the United States, subject to each component's regulatory status. The launch expands MRI from diagnostic imaging toward real-time cardiac intervention.
- On May 19, 2026, Philips introduced 4D MR-RT for abdominal radiotherapy simulation. The solution reconstructs as many as ten respiratory phases during free breathing and provides T1- and T2-weighted contrasts for moving anatomy. Philips stated that the product had received U.S. 510(k) clearance and a European CE mark.
- On May 11, 2026, GE HealthCare presented its next-generation MR program at ISMRM. The update covered the 510(k)-cleared SIGNA Bolt 3T system, SIGNA One workflow, SIGNA Sprint with Freelium, expansion of AIR Recon DL and research tools under SIGNA Studio. Several features remained pending clearance or limited to research use, so commercial status must be assessed product by product.
- Also on May 11, 2026, Philips unveiled Titanion, a work-in-progress 3T platform designed with 150 mT/m gradient strength, a 250 T/m/s slew rate and whole-body quantitative imaging capabilities. Titanion was not FDA cleared at the announcement date and was not available for sale, but the development signals continued competition in high-gradient 3T research and biomarker imaging.
Market Outlook, 2026–2035
U.S. MRI revenue is forecast to rise from USD 2.64 billion in 2026 to USD 3.95 billion in 2035. Growth will be steady rather than uniform. Capital-budget timing, hospital construction, interest rates and reimbursement can shift system orders between years, while software, coil and service revenue provides a more recurring base.
The market will retain a strong 1.5T center of gravity. Hospitals and outpatient sites use 1.5T for the broadest range of routine examinations, and replacement systems can deliver faster workflows without the full operating requirements of 3T. The 3T segment will gain value through advanced neuro, prostate, cardiac, musculoskeletal and research applications. Low-field equipment will record stronger percentage growth but will remain a smaller revenue category in 2035.
By the end of the forecast period, buyers will judge systems through total productive capacity. Scan duration, table turnover, repeat rates, staffing needs, power use, helium exposure, service uptime and upgrade access will determine the economic result. Vendors that prove improvements with site-level operating data will be better positioned than those relying on magnet specifications alone.
